Literature DB >> 8257147

Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long-wavelength UV light.

K Marutani1, M Matsumoto, Y Otabe, M Nagamuta, K Tanaka, A Miyoshi, T Hasegawa, H Nagano, S Matsubara, R Kamide.   

Abstract

A newly developed fluoroquinoline, Q-35 (8-OCH3), in which a methoxy group was substituted at the 8 position of the quinoline nucleus, was very stable under irradiation with long-wave UV light (UVA). Derivatives, a fluoroquinolone with no substitution (the 8-H analog) and one in which a fluorine was substituted (the 8-F analog), were degraded in their solutions by the UVA irradiation. The phototoxic inducibility by these derivatives was further studied in a murine model. When mice were dosed orally with 800 mg of Q-35 (8-OCH3) per kg of body weight, the maximum dose given, and exposed to the UVA light, no inflammatory lesions were observed in their ears. Ear redness was marked in mice given more than 12.5 mg of the 8-F analog or 200 mg of the 8-H analog per kg. Histopathological changes, edema, and infiltration of neutrophils were also observed microscopically in groups receiving the 8-H or 8-F analog but not in groups receiving Q-35 (8-OCH3). Similar inflammatory reactions were observed to occur in a dose-dependent manner with other available fluoroquinolone antibacterial agents such as lomefloxacin, enoxacin, norfloxacin, ciprofloxacin and ofloxacin. These results suggest that the introduction of a methoxy group at the 8 position of the quinolone nucleus is important for the reduction of phototoxicity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8257147      PMCID: PMC192253          DOI: 10.1128/AAC.37.10.2217

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  The loss of antibiotic activity of ciprofloxacin by photodegradation.

Authors:  G Phillips; B E Johnson; J Ferguson
Journal:  J Antimicrob Chemother       Date:  1990-12       Impact factor: 5.790

2.  Phototoxic bullous eruptions due to nalidixic acid.

Authors:  D A Birkett; M Garretts; C J Stevenson
Journal:  Br J Dermatol       Date:  1969-05       Impact factor: 9.302

3.  Enoxacin raises plasma theophylline concentrations.

Authors:  W J Wijnands; C L van Herwaarden; T B Vree
Journal:  Lancet       Date:  1984-07-14       Impact factor: 79.321

4.  Loss of antibiotic activity caused by photodegradation: in vivo studies.

Authors:  J Ferguson; G Phillips; J McEwan; T Moreland; B E Johnson
Journal:  Br J Dermatol       Date:  1988-10       Impact factor: 9.302

5.  Photosensitization drugs: nalidixic and oxolinic acids.

Authors:  D E Moore; V J Hemmens; H Yip
Journal:  Photochem Photobiol       Date:  1984-01       Impact factor: 3.421

6.  In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae.

Authors:  Y Gohara; S Arai; A Akashi; K Kuwano; C C Tseng; S Matsubara; M Matumoto; T Furudera
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

7.  The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis.

Authors:  T Jensen; S S Pedersen; C H Nielsen; N Høiby; C Koch
Journal:  J Antimicrob Chemother       Date:  1987-10       Impact factor: 5.790

Review 8.  Specific toxicologic aspects of the quinolones.

Authors:  W Christ; T Lehnert; B Ulbrich
Journal:  Rev Infect Dis       Date:  1988 Jan-Feb

Review 9.  Adverse effects of the fluoroquinolones.

Authors:  H Halkin
Journal:  Rev Infect Dis       Date:  1988 Jan-Feb

10.  Photoonycholysis induced by the fluoroquinolones pefloxacine and ofloxacine. Report on 2 cases.

Authors:  R Baran; P Brun
Journal:  Dermatologica       Date:  1986
View more
  17 in total

1.  Contribution of the C-8-methoxy group of gatifloxacin to inhibition of type II topoisomerases of Staphylococcus aureus.

Authors:  Masaya Takei; Hideyuki Fukuda; Ryuta Kishii; Youko Kadowaki; Yukiko Atobe; Masaki Hosaka
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

2.  Adverse reactions induced by NSAIDs and antibacterials: analysis of spontaneous reports from the Sicilian regional database.

Authors:  Giovanni Polimeni; Francesco Salvo; Paola Cutroneo; Ilaria Morreale; Achille Patrizio Caputi
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 3.  Tolerability of fluoroquinolone antibiotics. Past, present and future.

Authors:  P Ball; G Tillotson
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

4.  Combined use of in vitro phototoxic assessments and cassette dosing pharmacokinetic study for phototoxicity characterization of fluoroquinolones.

Authors:  Yoshiki Seto; Ryo Inoue; Masanori Ochi; Graham Gandy; Shizuo Yamada; Satomi Onoue
Journal:  AAPS J       Date:  2011-07-08       Impact factor: 4.009

Review 5.  Comparative tolerability of the newer fluoroquinolone antibacterials.

Authors:  P Ball; L Mandell; Y Niki; G Tillotson
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

6.  Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance.

Authors:  Y Dong; C Xu; X Zhao; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

7.  Photosensitivity reactions caused by lomefloxacin hydrochloride: a multicenter survey.

Authors:  J Arata; T Horio; R Soejima; K Ohara
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

Review 8.  Fluoroquinolone toxicities. An update.

Authors:  P S Lietman
Journal:  Drugs       Date:  1995       Impact factor: 9.546

9.  Flush induced by fluoroquinolones in canine skin.

Authors:  M Kurata; Y Kasuga; E Nanba; H Nakamura; T Asano; K Haruta
Journal:  Inflamm Res       Date:  1995-11       Impact factor: 4.575

10.  Efficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review.

Authors:  Peter Ball
Journal:  Curr Ther Res Clin Exp       Date:  2003-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.